Spartalizumab Biosimilar - Research Grade

Human

PDCD1ï؟½

5mg/ml

IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q15116

Blue ice

PD-1 limits T-cell activation as an inhibitory checkpoint and is one of the most investigated targets in immuno-oncology. This reagent is an unconjugated, non-therapeutic analog of spartalizumab, a recombinant anti-PD-1 monoclonal antibody intended for research use only. It is manufactured to in vivo standards in a low-endotoxin format and offered in scalable milligram to gram quantities for high-throughput workflows. Researchers use it in checkpoint-blockade functional assays, in vitro T-cell co-culture screens, and in vivo tumor-immunology models requiring a consistent reagent. Its reproducible formulation and scalable volumes support standardized results in bulk research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks